Methotrexate and misoprostol for early abortion

Area of Science:

• Reproductive Endocrinology
• Pharmacology
• Gynecology

Background:

• Methotrexate is a cytotoxic agent used for gestational trophoblastic neoplasia and ectopic pregnancy.
• Its cytotoxic effects on intrauterine trophoblast suggest potential for early pregnancy termination.
• Minimal side effects are noted with low-dose methotrexate.

Purpose of the Study:

• To test the hypothesis that methotrexate's cytotoxic effects on intrauterine trophoblast can induce abortion.
• To compare the efficacy of oral versus vaginal misoprostol in conjunction with methotrexate for early pregnancy termination.

Main Methods:

• Ten pregnant women (< 8 weeks' gestation) received intramuscular methotrexate (50 mg/m2).
• Patients were subsequently administered either oral misoprostol (600 mcg, n=4) or vaginal misoprostol (800 mcg, n=6) three days later.
• Abortion rates, time to abortion, and complications were monitored.

Main Results:

• Vaginal misoprostol (800 mcg) resulted in significantly higher abortion rates (p = 0.005) compared to oral misoprostol (600 mcg).
• Abortion occurred within 3-8 hours with vaginal misoprostol, while oral administration showed delayed or no abortion.
• No methotrexate side effects were observed; vaginal bleeding averaged 29 days with vaginal misoprostol.

Conclusions:

• Intramuscular methotrexate combined with vaginal misoprostol is an effective method for early pregnancy termination.
• Vaginal administration of misoprostol is superior to oral administration in this regimen.
• This combination therapy offers a viable medical alternative for early intrauterine pregnancy.